Shots:
- The global P-I/II/III (CLIMB-121 & 111) trials assessed Casgevy in sev. SCD & TDT pts (12–35 yrs), with 2yr. post-infusion follow-up, after which pts entered the ongoing 15yr. CLIMB-131 trial, with SCD pts followed for >5.5yrs & TDT for >6yrs.
- In SCD, 43/45 pts were VOC-free for ≥12mos., with mean VOC-free duration of 35mos. & all avoided hospitalization for sev. VOCs for ≥12mos. with mean duration of 36.1mos. in CLIMB 121 & 131 trials
- In TDT, 54/55 achieved ≥12mos. transfusion independence with Hb ≥9g/dL & mean duration of 40.5mos. & 1 remained transfusion-free for 14.8mos. in CLIMB-111 & 131; 39/56 discontinued iron removal therapy for >6mos. with improved ferritin & liver iron, plus pts maintained stable HbF & allelic editing
Ref: Newswire | Image: Vertex| Press Release
Related News:- Vertex Pharmaceuticals’ Alyftrek Receives the EC’s Approval to Treat Cystic Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
